Anavex Life Sciences (AVXL) Receiving Somewhat Positive News Coverage, Analysis Finds
News stories about Anavex Life Sciences (NASDAQ:AVXL) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anavex Life Sciences earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.1348374790059 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Anavex Life Sciences’ (AVXL) CEO Christopher Missling on Q3 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at Maxim Group (americanbankingnews.com)
- Anavex Life Sciences Corp. to Host Earnings Call (finance.yahoo.com)
- Anavex Life Sciences (AVXL) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS (americanbankingnews.com)
- Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results (finance.yahoo.com)
Anavex Life Sciences traded down $0.09, reaching $2.74, on Friday, according to MarketBeat Ratings. The company had a trading volume of 311,043 shares, compared to its average volume of 314,389. Anavex Life Sciences has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The firm has a market cap of $126.39 million, a P/E ratio of -8.30 and a beta of 1.15.
Several equities research analysts recently issued reports on the stock. HC Wainwright set a $10.00 target price on shares of Anavex Life Sciences and gave the stock a “buy” rating in a report on Tuesday, July 10th. Maxim Group initiated coverage on Anavex Life Sciences in a research report on Monday, July 9th. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research raised Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Tuesday, May 22nd. Finally, Noble Financial set a $7.00 price target on Anavex Life Sciences and gave the stock a “buy” rating in a research report on Wednesday, May 16th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Anavex Life Sciences has a consensus rating of “Buy” and a consensus price target of $6.55.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.